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REGRESSION AND PROPENSITY SCORE APPROACHES FOR
CONTROLLING FOR TREATMENT SELECTION BIAS USING
MONTE CARLO SIMULATION
Wang J, Wu Y, Irish WD
RTI Health Solutions, Research Triangle Park, NC, USA
OBJECTIVES: In the absence of well-controlled clinical studies,
medical records provide a potential wealth of information about
the value of treatments; however, differences in pretreatment
patient or other characteristics may inﬂuence treatment assign-
ment and lead to biased estimates of treatment effects. Several
strategies are available to reduce treatment selection bias. These
include multivariable regression (MR) and propensity score 
(PS) techniques. Cepeda and colleagues (Am J Epidemiol
2003;158:280–7) demonstrated that PS is less biased than MR
when the ratio of number of events to number of confounders
(REC) is less than 8 by simulation. Using methods deemed more
appropriate than Cepeda, we set out to evaluate conditions upon
which their conclusions may be incorrect. METHODS: Monte
Carlo simulation was performed in which each subject: 1) had
10 confounders (Zk : k = 1, . . . , 10) generated using normal and
Bernoulli distributions; 2) was assigned to exposure or non-
exposure with probability p determined by confounding vari-
ables; and 3) was given a binary response variable with
probability g determined by confounder and exposure strength
of association. For each simulation, binary logistic regression
was used to: 1) generate individual PSs by regressing exposure
variable on the confounder variables Z; and 2) estimate PS- and
MR-adjusted treatment effects. Process was repeated 1000 times
to evaluate bias and power of the statistical test. RESULTS: MR
method produces asymptotically unbiased estimate of treatment
effect; a result that is only marginally affected by the REC. Even
when REC was 4.5, MR produced unbiased estimate of treatment
effect with larger sample size. Contrary to the MR method, PS
produces estimates that are consistently lower than the true effect
regardless of sample size or REC. Power is always lower using the
PS method. CONCLUSION: Results suggest PS method provides
no statistical advantage over traditional MR; a conclusion that
is contrary to Cepeda et al recommendations.
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CONTROLLING FOR COMORBIDITIES USING VARIATIONS OF
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OBJECTIVES: To compare variants of the Deyo-modiﬁed Charl-
son Comorbidity Index (DM-CCI) as comorbidity adjustors
when predicting annual health care costs attributable to a spe-
ciﬁc condition using administrative data. METHODS: We
extracted all medical claims for Medicare individuals >65 with
continuous coverage for Medicare parts A and B (N = 1.2
million) during 2003 and 2004 from ﬁles obtained from the
Centers for Medicare and Medicaid Services. In order to estimate
annual expenditures attributable to overactive bladder (OAB),
we used multiple regression techniques that adjusted for demo-
graphics (age, race, region, gender) and comorbidities. Comor-
bidities were deﬁned in four ways. Method 1 used the DM-CCI
as the only measure of comorbidity. Method 2 used the DM-CCI
plus indicator variables for other conditions not included in the
DM-CCI that were not considered sequelae of OAB (hyper-
lipidemia, depression/anxiety, hypertension, heart disease,
osteoarthritis, cataracts/glaucoma, enlarged prostate, muscu-
loskeletal conditions excluding arthritis, GERD, and neurologi-
cal conditions). Model 3 was identical to Model 2 but excluded
depression/anxiety. Model 4 was identical to Model 2 but also
included events and conditions related to OAB (UTIs, skin in-
fections, falls/fractures, and vulvovaginitis). RESULTS: Mean
annual expenditures attributable to OAB were $2278, $825,
$996, and $94 per individual with OAB for Models 1, 2, 3, and
4 respectively. CONCLUSION: Attributable costs calculations
using regression techniques may be very sensitive to the speciﬁ-
cation of comorbid conditions. Analysts need to avoid both the
omission of key confounders, which can overstate the cost of a
condition (e.g., Model 1), and over-speciﬁcation, which will
understate the cost of a condition by attributing too much cost
to comorbidities that are actually related to the condition of
interest (e.g., Model 4). Candidate comorbid conditions must be
considered carefully before they are included in regression
models to predict condition-speciﬁc attributable costs.
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OBJECTIVES: To systematically evaluate the impact of time
horizon choice on the incremental cost-effectiveness ratio (ICER)
under varying assumptions regarding treatment effectiveness,
costs and discount rate. METHODS: We developed a Markov
model, comparing two hypothetical strategies and predicting
marginal quality adjusted life years (QALYs), costs and ICERs
as a function of time horizon (ranging from 5 to 50 years). We
assume that clinical trial data is available for 5 years of follow
up. The model was analyzed for the following scenarios: extrap-
olation of survival beneﬁt (optimistic, intermediate, conserva-
tive), prediction of treatment costs (one time costs only, constant
continued incremental cost with/without cost decrease after 10
years), and discount rate (undiscounted, same discount rate for
QALYs and costs, differential discount rate for QALYs and
costs). RESULTS: The effect on ICER is greatest when compar-
ing a 5 year to a 10 year or longer time horizons. For most sce-
narios the ICER does not change much when extending the time
horizon beyond 15 years (less than 20% relative change in
ICER).The choice of time horizon conditional on the extrapola-
tion method of survival beneﬁt (optimistic and intermediate sce-
narios) for one time cost scenarios had the greatest impact on
reducing the ICER (reduction of >60% if using 10 year instead
of 5 year time horizon). In scenarios with continued costs, the
ICER was sensitive to a cost decrease after 10 years but less sen-
sitive to the discount rate. CONCLUSION: Current guidelines
suggest adopting a lifetime time horizon when a mortality beneﬁt
is present. Our study measures the bias associated with adopt-
ing the time horizon of a clinical trial, a common practice. Most
susceptible to bias are scenarios with one time costs as the ICER
is most sensitive to the chosen extrapolation method for survival
beneﬁts. The choice of time horizon and its impact on ICER
warrant careful consideration.
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EMPLOYEES WITH FIBROMYALGIA: MEDICAL COMORBIDITY,
HEALTH CARE COSTS,AND WORK LOSS
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OBJECTIVES: To compare health care use, health care costs,
and work loss costs in employees with ﬁbromyalgia (FM) to
